Clinical Trial Update: Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of dasatinib and venetoclax in patients with early chronic-phase Philadelphia chromosome-positive chronic myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Sprycel (dasatinib) (dasatinib)
• Venclexta (venetoclax) (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING